Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR-0202 in advanced or metastatic relapsed/refractory carcinomas
NCT06999187Phase 1Recruiting
- Sponsor
- Dren Bio
- Start
- Jun 2025
- Primary completion
- Jul 2027
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of DR-0202 in triple-negative breast cancer (TNBC), breast cancer, non-small cell lung cancer (NSCLC) and 9 more (8 arms), sponsored by Dren Bio. Primary endpoint: Treatment-Emergent Adverse Events. Started Jun 2025; status: recruiting.
02
Drugs
DR-0202
03
Conditions
triple-negative breast cancer (TNBC)breast cancernon-small cell lung cancer (NSCLC)Cervical Cancer (CC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06999187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06999187.